<DOC>
	<DOC>NCT01210690</DOC>
	<brief_summary>The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when treated according to routine clinical practice. Their data will be collected until they reach the age of 13 months.</brief_summary>
	<brief_title>Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution</brief_title>
	<detailed_description>This non-interventional sentinel sites post-authorization safety study (PASS) aims to collect additional data on use of Keppra® (Levetiracetam) oral solution in clinical practice, and on efficacy and safety of Keppra® (Levetiracetam) in infants younger than12 months. Epileptic patients between the age of 1 month and 11 months inclusive can be invited for participation to the non-interventional sentinel sites PASS, after the physician has decided to initiate therapy with Keppra® (Levetiracetam) oral solution (100 mg/ml bottle) and patient has so far been treated with Keppra® (Levetiracetam) for no longer than 10 days. The patients will be followed and their data will be collected until they reach the age of 13 months.</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>diagnosis of epilepsy being treated with Keppra® Oral Solution aged between 1 month and 11 months inclusive at study baseline</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra® Oral Solution</keyword>
	<keyword>Keppra® in Children</keyword>
</DOC>